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Abstract
The p53 tumor suppressor regulates its target genes through sequence-specific binding to DNA response elements (REs).
Although numerous p53 REs are established, the thousands more identified by bioinformatics are not easily subjected to
comparative functional evaluation. To examine the relationship between RE sequence variation—including polymor-
phisms—and p53 binding, we have developed a multiplex format microsphere assay of protein-DNA binding (MAPD) for
p53 in nuclear extracts. Using MAPD we measured sequence-specific p53 binding of doxorubicin-activated or transiently
expressed p53 to REs from established p53 target genes and p53 consensus REs. To assess the sensitivity and scalability of
the assay, we tested 16 variants of the p21 target sequence and a 62-multiplex set of single nucleotide (nt) variants of the
p53 consensus sequence and found many changes in p53 binding that are not captured by current computational binding
models. A group of eight single nucleotide polymorphisms (SNPs) was examined and binding profiles closely matched
transactivation capability tested in luciferase constructs. The in vitro binding characteristics of p53 in nuclear extracts
recapitulated the cellular in vivo transactivation capabilities for eight well-established human REs measured by luciferase
assay. Using a set of 26 bona fide REs, we observed distinct binding patterns characteristic of transiently expressed wild type
and mutant p53s. This microsphere assay system utilizes biologically meaningful cell extracts in a multiplexed, quantitative,
in vitro format that provides a powerful experimental tool for elucidating the functional impact of sequence polymorphism
and protein variation on protein/DNA binding in transcriptional networks.
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Introduction
The prominent tumor suppressor p53 is a transcription factor
(TF) that regulates a vast network of genes. Functional evaluation
of binding to its target DNA response elements (REs) is a key step
in understanding the many events that can lead to tumorigenesis.
Following activation, p53 localizes to the nucleus, forms a
tetramer, binds to REs and transactivates or suppresses target
genes[1,2]. The well-established p53 RE consensus sequence
consists of two 10-nt half-sites (RRRCWWGYYY-N*-
RRRCWWGYYY, R=purine, Y=pyrimidine, W=A/T and
N*=0 to 13-nt spacer) [3] and p53 binding to these DNA
elements is a necessary event for p53-regulated gene expression.
The relationship between p53 activation, binding and in vivo gene
transactivation remains an important area of investigation [4].
Experimental studies have identified numerous bona fide REs
necessary for p53-regulated transactivation, and thousands of
potential sites have been implicated by bioinformatics [5,6]. The
presence of single nucleotide polymorphisms (SNPs) in REs may
impact transcription factor binding and result in altered gene
expression. Genetic variation in TF binding is a significant
evolutionary mechanism in mammals [7] and directs species-
specific gene expression [8]. In human populations, response
element variation is known to alter cellular processes including
diabetes [9], development [10], angiogenesis [11] and susceptibil-
ity to many other diseases including cancer [12]. With the
accelerating identification of noncoding, disease- and expression-
associated SNPs through genome-wide association studies [13],
evaluating the functional and mechanistic consequences of
regulatory SNPs is a general problem in human genetics. We
have identified several hundred SNPs in the human genome that
reside within putative p53 REs [5]. Assessing the impact of these
RE SNPs is of direct relevance to p53 function in the cell cycle,
DNA repair, apoptosis and subsequent tumorigenesis.
Binding of p53 or its mutants to REs has been assessed by in
vitro techniques such as electrophoretic mobility shift (EMSA),
surface plasmon resonance, fluorescent anisotropy and chromatin
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experimental limitations. We sought to test p53 binding to a large
number of defined sequences, including single nucleotide variants,
with cell extracts generated from different experimental conditions
using an approach that would be amenable to high sample
throughput and replication. Microsphere-based flow cytometric
assays utilize fluorescent-dyed beads (,6 micrometer micro-
spheres) coated with molecules such as nucleic acids or peptides
[14]. Beads are placed in an assay medium containing biological
targets (e.g., cell extracts containing p53 or ERa) where
interactions can take place. Each bead type has a distinct spectral
signature and up to 100 bead types per reaction can be used. A
dual laser-equipped flow cytometer detects both the bead identity
and a fluorescent reporter dye attached to the target of interest
that is captured on the bead. The fluorescence signal intensity
reflects relative quantification of target/bead interaction. This
technology has been adapted to many assays [15], including RNA
expression analysis [16], serum cytokine analysis [17,18] and high-
throughput genotyping [18,19,20,21].
Based on this platform, we developed a highly reproducible
general approach for performing large-scale quantitative studies of
protein-DNA binding using p53 or other transcription factors,
such as ERa Importantly, this microsphere assay for protein-DNA
binding (MAPD) generates biologically-meaningful binding data
using nuclear extracts from human cells, permitting flexible
experimental designs. We show that the MAPD approach provides
high resolution and utility in the functional evaluation of p53
binding to RE variants, including single nucleotide changes in
REs, making it an effective tool in modern genomics research.
Comparing experimental and computed binding values based on a
position weight matrix (PWM) model, commonly used for
evaluating TF binding, we demonstrate that subtle changes in
the binding sequence have functional consequences that are not
captured by PWM models. Furthermore, using a panel of p53 REs
and p53 RE SNPs, we observed patterns of binding that are highly
correlated with luciferase-based transactivation measurements in
mammalian cells. The p53 mutants, S121F and R175H, displayed
a change in binding specificity and a loss of binding respectively.
The binding properties of these mutants are consistent with their
previously described effects on gene expression [22]. While in vitro
binding measurements are not a surrogate for ChIP or gene
expression studies, this method allows quantification of a necessary
step in transcription. This work demonstrates that MAPD can not
only be used to evaluate RE sequence variation and SNPs, but
may also be useful for probing functional changes in the protein
structure of DNA binding proteins.
Results
Multiplex Binding Measurements of Activated p53 with
Known REs
The effects of sequence variation among binding sites for a
given TF have been difficult to quantify in protein-DNA binding
experiments. We developed a fluorescent microsphere-based
approach to interrogate the interaction between p53 and its target
REs (Figure 1 and S1). Double-stranded DNA fragments bearing
p53 RE sequences (ConA, ConC, p21, PUMA, GADD45) and a
negative control (WRNC) were uniquely linked to different sets of
fluorescent microsphere beads (see Materials and Methods and
Supporting Information for oligonucleotide design). Equal quan-
tities of the 6 bead types were combined. The p21 RE, a strong
binding sequence, was used as a positive control. ConA and ConC
are both perfect matches with the p53 consensus RE and have
been demonstrated to function as strong binding REs in a p53
model system [23] and human cells (Menendez, Jordan and
Resnick, unpublished) with ConA being more responsive to p53.
p53 binding to the strong RE from p21 and to the moderate-to-
weak REs from PUMA and GADD45, respectively, are well
established [24,25].
Figure 2 displays p53 binding after incubating the 6-plex beads
with nuclear extracts from human lymphoblastoid cells that were
either not treated (NT), containing small amounts of activated p53,
or treated with doxorubicin (DOXO), inducing high levels of
activated p53 [26]. MAPD could detect p53 binding in both. The
Figure 1. Microsphere assay for protein-DNA (MAPD) binding.
Double-stranded oligonucleotides containing p53 binding sequence of
interest and single-stranded tag overhang were hybridized to FlexMap
beads bearing complementary anti-tag sequence. Multiplex groups of
beads were prepared and incubated with nuclear extracts containing
transcription factor. Primary and secondary antibodies were added,
beads were sorted and fluorescence signal was quantified for each bead
type and normalized by biotin/streptavidin/phycoerythrin signal to
adjust for bead-specific signal effects.
doi:10.1371/journal.pgen.1000462.g001
Author Summary
Characterizing the functional roles of gene regulatory
sequences and the impact of genetic polymorphism on
protein-DNA binding are rapidly growing areas of geno-
mics. The p53 tumor suppressor regulates its target genes
through sequence-specific binding to DNA response
elements, and we have developed a multiplex format
microsphere assay (MAPD) to probe how sequence
variation alters p53 binding. Testing pools of multiplexed
oligonucleotides that contain numerous p53 binding
targets or different sequence variants, we demonstrate
that subtle changes in target sequence can impact p53
binding, and these effects are not captured by commonly
used computational binding models. A group of single
nucleotide polymorphisms was examined and binding
profiles closely matched gene expression measured in a
parallel system. We also observed distinct binding patterns
that were characteristic of transiently expressed wild type
and mutant p53s, suggesting that this method may be
useful for probing the impact of protein structural
variation on DNA binding. MAPD utilizes biologically
meaningful cell extracts in a multiplexed, quantitative
format that provides a powerful experimental tool for
elucidating the functional impact of sequence polymor-
phism and protein variation on protein/DNA binding in
transcriptional networks.
Sequence Variation and p53 DNA Binding
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of a biotinylated reverse oligonucleotide on the same bead/oligo
construct conjugated with phycoerythrin/streptavidin as described
in the Materials and Methods. Binding values are relative to the
biotin signal. The ConA sequence (black bar) showed appreciable
binding (0.073+/20.0045) in the NT extract, and this level was
,30-fold greater than the negative control (WRNC: 0.0023+/
20.0009). Relative to the NT values, nuclear extracts from
DOXO-treated cells had a 17-fold increase for ConA (1.26+/
20.089), an 8-fold increase for p21 (0.27+/20.023) and a 5-fold
increase for weak-binding GADD45 (0.054+/20.006). The
DOXO-induced ConA signal was ,180-fold greater than the
DOXO negative control value. For GADD45 there was an 8-fold
greater signal over the negative control, demonstrating the large
dynamic range of the assay for both strong and weak binding
sequences.
To examine binding specificity, the bead set was presented to
nuclear extracts (NT and DOXO) along with excess of
oligonucleotide designed to directly compete for binding
(Figure 2, Competing Oligo). Specificity for p53 binding was
clearly demonstrated by abolishment of the signal in extracts from
both NT and DOXO (see also Figures S2 and S3). An excess
amount of a noncompeting oligonucleotide was used to maximize
signal by blocking nonspecific binding (see optimization in Figures
S2, S3). MAPD detected DOXO-activated p53 binding over a
broad dynamic range (,2.5 logs) and nuclear extract concentra-
tions (Figure S4). Using extracts with different quantities of p53
allows quantitative comparisons of biochemical properties (Table
within Figure S4). To examine the general applicability of MAPD
for measuring protein-DNA binding, we also created beads
bearing different estrogen receptor a binding elements and
measured ERa binding. ERa binding data is presented in the
Supporting Information (Figure S5A,B).
Impact of Sequence Variation on p53 Binding
MAPD is highly suited to experiments such as site-directed
mutagenesis of REs or SNP functional analysis, as shown in
Figure 3A for p53 RE of p21, designated p21LWT. To investigate
the importance of individual nucleotides on p53 binding, NT and
DOXO-treated cell nuclear extracts were hybridized with 16
variants of the p21 RE in a 19-plex reaction that included two
positive controls (ConA and p21LWT) and a negative control
(WRNC). DOXO-treated cell extracts produced higher binding
for all sequences. The p21 RE produced strong binding signals
relative to WRNC, both when embedded in its native flanking
sequence (p21LWT 0.62+/20.021) or an unrelated flanking
sequence (p21GL3 0.58+/20.021; sequences are listed in
Supporting Information). The perfect consensus p53 RE, ConA,
showed a stronger signal (1.21+/20.083) relative to p21LWT.
Changing the p21LWT sequence at nt-11 from C to G (Figure 3A
11C.G), a change favoring consensus, resulted in binding that
was slightly higher (0.64+/20.038) than the native p21LWT.
Moreover, when positions nt-11 and nt-20 in p21LWT were
simultaneously changed to better match the consensus (Figure 3A,
11C.G; 20G.C), there was a 29% increase in p53 binding (from
0.64 to 0.83+/20.069). This provides an example of how
Figure 2. Detection of binding interactions between activated p53 and a set of multiplexed REs. A six-plex set of oligonucleotide-
conjugated beads, carrying p53 binding sites (ConA, ConC, p21, PUMA, GADD45) and a negative control (WRNC) were incubated with nuclear
extracts for 60 minutes, and p53 binding was measured. Nuclear extracts were from non-treated lymphoblast cells (NT) or cells treated with 1 mM
doxorubicin (DOXO) for 24 hrs. Addition of a competing oligonucleotide demonstrates binding specificity. Relative binding was obtained for each RE
tested. The split vertical scale allows display of data from high and low values. Values shown are the means for each bead type+/2SD (n=3).
doi:10.1371/journal.pgen.1000462.g002
Sequence Variation and p53 DNA Binding
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factor binding. Among mammalian p53 REs, the most conserved
positions are C and G nucleotides 4, 7, 14, and 17, and many
studies have observed that changes at these positions strongly
impact p53 transactivation [3,4,5,6,27,28,29]. The present data
demonstrate that these effects are due to decreased p53 binding.
Experimental Support for Computational Binding Models
TFBS predictions using position weight matrix (PWM)
calculations are ubiquitous in the genomics literature. Binding
sequences gleaned from publications (or a database such as
TRANSFAC) are used to create a PWM to evaluate and score
new sequences. Such statistical models determine the nucleotide
frequency in a sequence motif database under the simplifying
assumption that the sampled sequences are bona fide functional
REs with similar binding properties and all nts act independently.
Experimental quantification of TF binding strength has been
laborious. Importantly, while TF binding strength is expected to
greatly influence function of the p53-regulated network, or other
networks, this information is rarely incorporated into binding
models or RE prediction. To demonstrate the impact of SNPs on
p53 binding and to show how quantitative binding data may be
useful for refining RE prediction models, we generated a set of 60
oligonucleotides, each bearing a single nt variant of ConA along
with positive and negative controls to yield a 62-plex experiment.
Figure 3B displays p53 binding to the 62 oligonucleotides
(Figure S6 shows NT binding) and clearly reveals differences in the
impact of both the position and type of base-change (e.g., purine to
purine, purine to pyrimidine) and also differences from the PWM
model prediction. Comparing PWM data (black bars) to
experimental data (open bars) for the core motif (4C, 7G, 14C,
17G, brackets), there is a general similarity in pattern, but for
many base-changes, the correlation of PWM with binding is poor.
For example, in the PWM model, changes at positions 3G.C,
8T.G, 12G.C, or 18T.G have little effect (,20%), but our
results show a .75% binding reduction at these positions. It is
clear that PWM values, which vary by only 2-fold cannot provide
a robust prediction of binding, which varies as much as 13-fold just
among these sequences. Since sequences used as input to PWM
models typically have been evaluated in qualitative binding assays
such as EMSA, it is not surprising that PWM models often have
limited predictive ability. Using the technique of Veprintsev and
Fersht [30] we have generated a sequence logo from the binding
data that can be compared with the traditional consensus sequence
(Figure 4). The sequence logo derived from binding data differs
from the traditional PWM model consensus, yet the pattern for the
natively DOXO-activated p53 in nuclear extracts is generally
consistent with the recent in vitro half-site binding analysis using a
purified, ultra-stable mutant p53 and fluorescent anisotropy [30].
The binding-based PWM supports a strong role for C and G
nucleotides at positions 4, 7, 14, 17 and also for G at position 3.
The A at position 5 is characteristic of very strong p53 binding
REs. In addition, these data were generated using 20mers and
appear to support binding strength asymmetry within the half-site
(nt 1–5 versus nt 6–10) and also asymmetry across the two half-
sites, as suggested by the p53 ChIP data of Wei et al [31] and the
model of Riley et al [28]. Incorporating detailed experimental
binding data will allow for more accurate computational binding
models. Preliminary evidence for improved model building is
demonstrated in Figure 4. The binding-based PWM model was
tested on the panel of bona fide RE sequences listed in Table S1.
Experimental binding values for these REs are plotted versus
predicted binding values using the traditional PWM (4C) and
binding-based PWM (4D) models. The correlation coefficient is
considerably improved (from r
2=0.40 to r
2=0.64) by the use of
binding data in the position weight matrix model. While this
represents a limited experimental data set and a simple linear
model, it suggests that binding information may be useful for
informing the identification of binding sites. We suggest that
experiments examining a large set of strong to weak p53 REs (with
various quarter-site orientations, insertions/deletions and spacer
lengths) will provide data that can be incorporated into more
sophisticated computational models, such as those proposed by
Veprintsev and Fersht [30], and Riley, et al [28], and this should
greatly improve p53 binding site prediction.
Evaluation of SNPs in p53 Response Elements
SNPs in 8 putative p53 REs were identified using the
bioinformatics approach described in Tomso et al [5]. Sequences
are shown in Table S1. Oligonucleotides containing the predicted
weak and strong alleles for these p53 REs were placed on
microspheres and evaluated for binding to activated p53 in
nuclear extracts (Figure 5). Negative and positive control
oligonucleotides were hybridized in parallel in the multiplexed
reaction and nuclear extract from untreated cells was also tested as
a negative control (mean binding to p21 probe for untreated cell
extracts was 1.6%+/20.19%, n=6 of the Doxo treated value);
binding to p21 was consistent with p53 content assessed by western
blot and TransAm ELISA. Among these putative p53 REs, the
predicted strong alleles for REs in ADARB1, ARHGEF7, and
Figure 3. Sequence variation affects p53 binding. A) Evaluating the impact of single nucleotide variations in p21 RE on p53 binding using
nuclear extracts from untreated and DOXO-treated cells. A set of 19 oligonucleotides, each conjugated to a unique bead, were multiplexed and
treated with 1.75 mg of non-treated nuclear extracts (NT: checkered bar) or activated nuclear extracts (black bar: DOXO-treated lymphoblastoid cells).
Relative binding intensity is shown on the horizontal axis (note the break in the scale to accommodate the signal from all oligonucleotides). Relative
binding values were obtained for each oligonucleotide as discussed in Materials and Methods. The oligonucleotide bearing the p53 consensus
sequence (ConA) is first on the list (top left Y-axis) followed by wild type p21RE (p21LWT). p21GL3 bears the same 20-nt RE as p21LWT but with a
synthetic backbone sequence from pGL3 vector. Fifteen single or double variants of p21 RE are shown. The p21 sequence is shown as inset. The
number denotes the numerical position of the base within the p21 RE. Arrowheads point to the nts that have been chosen for alteration. WRNC is a
negative control oligonucleotide and carries a nonbinding sequence in the same backbone as the other oligonucleotides shown with the exception
of P21GL3. Values shown are the mean+/2SD (n=3). B) Multiplex binding measurements of 60 variants of a p53 consensus sequence. Sixty
oligonucleotides, each bearing a single nucleotide variation of the p53 consensus binding site (ConA=GGGCATGTCCGGGCATGTCC) were generated.
ConA sequence is shown in large letters under arrow. CATG core of each half-site is shown in a right-facing bracket. Systematic base substitutions at
all positions within ConA are shown in small letters. For instance, 1G.C is an RE with the first G converted to a C. In addition, a positive control bead
(ConA RE) and a negative control bead (WRNC: lacks a p53 binding RE) were included. Equal amounts of each microsphere type were mixed to
generate a multiplex of 62 bead types. Following treatment with activated nuclear extracts (DOXO-treated or untreated lymphoblastoid cells, Figure
S3), the relative binding intensity (value shown on upper horizontal axis) was obtained for each oligonucleotide (white bar) as discussed in Materials
and Methods. Bar values are means for each bead type+/2SD (n=3). The black bar graph in the background (e.g. black bars) shows the calculated
PWM value for each variant oligonucleotide tested (scale depicted on the lower horizontal axis). A list of PWM values for REs used can be found in
Supporting Information.
doi:10.1371/journal.pgen.1000462.g003
Sequence Variation and p53 DNA Binding
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binding, a level that is similar to PUMA and GADD45 (Figures 2
and 6). With the exception of REs upstream of DCC and SEI1, we
observed that the predicted weak alleles showed significantly
reduced binding. SNPs that altered the conserved core sequence
(ADARB1, EOMES, RRM1 and TLR8) showed dramatic
reductions in binding. This approach to functional evaluation of
TF binding site SNPs would be useful for rapid screening of
candidate SNPs in TF binding sites identified through bioinfor-
matics or whole genome association studies.
Assessing the Binding Spectrum Phenotype of Wild Type
vs. Mutant p53 Proteins
The p53 protein is a master regulator of the cell cycle, DNA
repair and apoptosis. p53 activation state is dependent on tissue
type and activating stimulus [2] and may impact binding, but few
experiments have explored this idea. Using a panel of p53 target
REs to assess binding phenotype, we examined nuclear extracts
containing activated p53 from different human cell types
(Figure 6A). To compare the p53 binding spectra for these
functional p53 molecules, we added equal quantities of p53
protein based on western blotting (Figure 6B insert) and
normalized binding values from each cell type by setting
p21LWT equal to 1. Both DOXO-induced and wt p53 binding
spectra are shown in Figure 6A; with binding levels for most REs
showing little difference (see also Figure S7A). While the profiles
are remarkably similar, given that p53 is derived from two
different cell types and two types of stimulus, some probes display
differences in binding. The very strong ConA RE (perfect
consensus) and the 14-3-3s RE showed somewhat increased
binding with DOXO treatment relative to wt p53, while
GADD45, PCNA and MDM2 REs displayed reduced binding.
Given the difference between these cell preparations, it is unclear if
the binding differences observed are biologically meaningful.
While treatment-specific, posttranslational modifications, such as
acetylation at lysine 317, phosphorylation at serine 33 or cofactor
interactions, have been hypothesized to mediate p53-mediated
gene expression and/or binding [1,2,32,33], this may not be the
case for some established tumor cell lines [34].
In general for both DOXO-activated and wt p53, we observed
that p53 REs from cell cycle arrest genes (p21LT, 1.22; 14-3-3s,
1.26) and DNA repair genes (p53R2, 1.02; PCNA, 0.33;
GADD45, 0.44) showed greater relative binding than REs from
apoptotic response genes (PUMA, 0.42; NOXA, 0.12; AIP1, 0.23;
BAX-B, 0.07). Importantly, these wild type patterns recapitulate in
vivo transactivation experiments using a reporter assay in SaOS2
cells expressing p53. Figure 6A (inset) shows the strong correlation
between p53 binding and transactivation capability of p53 REs
measured in mammalian cells for several known p53 target gene
REs (R
2=0.97, p=4.39E-05).
Mutations in p53 that lead directly to tumor growth are often
described as having a loss- or gain-of-function, as well as
dominant-negative phenotype [35,36]. The basis for these
descriptive names is presumed to be structural changes in the
protein that lead to functional effects and influence consequent
tumor phenotype. As shown in Figure 6B, p53 mutants carrying
DNA binding domain changes, R175H and S121F (previously
characterized in SaOS2 cells [22]), displayed dramatically
attenuated binding compared to wild type p53 (Figure 6A, 6B).
However, not all target REs are affected to the same extent. The
classical tumor suppressor R175H p53 mutant (grey stippled bar)
appears to abolish binding entirely as expected and several other
loss-of-function, DNA-binding domain mutants (G245S, C277W,
G279E) tested also showed total loss of binding (data not shown).
Notably, the change-of-spectrum S121F mutant (open bar)
displays significantly reduced binding for most REs compared to
wt p53 (mean reduction=51%) but S121F retains strong binding
for several REs, particularly those found upstream of the NOXA,
BAX-B, RGC and CycG genes (noted by # symbol). This
alteration in binding profile could translate to differences in
transactivation and eventual phenotypic consequences [22,37].
Discussion
Understanding variation in complex biological responses, such
as those mediated by the p53 tumor suppressor, requires
integrating bioinformatics with experimental approaches that
reveal fundamental molecular events and their phenotypic
consequences at the cellular level. The relationship between the
degree of DNA binding and target gene transactivation has been
the subject of many studies and there is considerable interest in
how human genetic variation in TF binding sites may impact gene
expression and disease susceptibility [5,9,10,11,38,39,40,41,42].
Figure 4. Sequence logos for p53 consensus created from two
datasets. The height of the letter indicates the frequency or binding
preference at that nucleotide position in the RE. A) Traditional position
weight matrix with p53 RE sequences from Table S2. B) Sequence logo
developed from the binding data (Figure 3B) using a modified approach
of Veprintsev and Fersht [30]. Binding values were put into a binding
position weight matrix (BPWM) and the letter height represents
experimentally determined binding preference. C) Binding values for
bona fide p53 RE sequences (as in Figure 6 and Table S1) plotted
against traditional PWM model prediction (4C) and binding based
model prediction (4D). The correlation between PWM calculation and
measured binding improved from r
2=0.40 with the traditional PWM
model (Figure 4C) to r
2=0.64 with binding-based model (4D).
doi:10.1371/journal.pgen.1000462.g004
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evaluated their impact on expression or binding [5,30]. The
present results suggest that MAPD can be useful for assessing the
magnitude of p53 binding to newly discovered candidate
sequences and also for evaluating the impact of SNPs or mutations
in those sequences.
Whole genome association studies frequently identify SNPs in
gene regulatory regions containing putative TFBSs; assessing TF
binding using the approach outlined here is one practical way to
evaluate the effects of regulatory region SNPs. One issue in
developing good prediction of TFBSs has been the lack of
quantitative binding data. We show that integrating binding
information from site-directed mutagenesis of a p53 consensus
sequence into a computational binding site model improves
prediction for a second set of REs.
We used MAPD to investigate sequence-specific binding
between p53 protein and a number of known and well-studied
REs in the p53 pathway. Various in vitro assays have suggested
that p53 has a higher affinity for REs in cell-cycle arrest and DNA
repair genes than the REs in apoptosis genes [4,24]. Similar
observations were obtained in vivo using a yeast-based system
[22,23], and the present results are in agreement. This is also
supported by Riley et al, who report that apoptosis-related p53
REs differ more from consensus binding sequence than cell cycle-
related REs. In addition an evolutionary analysis [43] indicates
that p53 RE sequences in human apoptosis genes tend to diverge
considerably from those of rodents—although some weak binding
REs do demonstrate strong evolutionary conservation.
We observed a strong correlation between binding to target p53
REs and p53-driven luciferase gene expression in mammalian cells
(Figure 6A). We have also seen that binding correlates with
expression for the p21 RE when constructed with variable numbers
of nucleotides between p53 half-sites [44]. These correlations
suggest that our in vitro binding assay using p53 in nuclear extracts
may be a surrogate for some in vivo transactivation studies.
However, further work to evaluate binding to full length native
promoter sequence with direct comparisons to chromatin IP and
expression is needed [45,46]. The importance of p53 binding has
been highlighted by Shaked et al al [34] who reported that p53
activation status and RE occupancy differ between tumor cell lines
and normal primary cells. Our approach, assessing binding with
nuclear extracts, can be used with tumor lines, EBV transformed
lymphoblasts or normal primary cells. This will allow quantitative
evaluation of the impact of post-translationally modified and
activated wt p53 on binding to target gene REs as in Figure 6, or
under various stress and DNA-damaging situations as in Shaked et
al [34]. Given that p53 mutations are the most common genetic
changes in cancer and are a major determinant of treatment
outcome [35,36], the MAPD system may be useful in assessing the
impact of mutations on p53 RE interactions (Figure 6B). Since
radiation and alkylating agents are primary therapies in cancer
treatment, understanding how exposures affect p53 activation and
Figure 5. Evaluation of p53 binding to response element SNP alleles. Binding for predicted strong (Dark bars) and weak (open bars) alleles
of the polymorphic sequence is shown relative to p21 RE binding (100%). Each bar represents the mean of 3 experiments carried out on different
days and performed in triplicate (error bars represent SD). Positive and negative control oligonucleotides (left side) were included in each experiment
and each sample was tested with a negative control extract (data not shown). This experiment was replicated using p53 extracts generated from a
second tissue type (U2OS cells, Figure S8). These results are in close agreement with evaluation of these SNP alleles when cloned into a luciferase
construct and transfected into SaOS2 cells expressing p53 (Tomso et al. [5]).
doi:10.1371/journal.pgen.1000462.g005
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and treatment response [35,36].
TF binding to REs is a necessary step in regulating
transcriptional networks [8]. EMSA and chromatin immunopre-
cipitation (ChIP) have been essential in advancing the study of
gene regulation. However, both approaches are low in sample
throughput, labor–intensive, difficult to quantify and have a
limited dynamic range. More recently, ChIP combined with
microarrays [34] or sequencing, and protein binding arrays
[47,48] have allowed parallel analyses of TF binding to thousands
of sequences, and these techniques are highly effective for
qualitative discovery of binding sites. However, currently these
approaches have experimental constraints, including relatively low
sample throughput, uncharacterized variability, and are expensive.
Surface plasmon resonance and fluorescence anisotropy are useful
for determining detailed biochemical parameters, but like protein
binding arrays are currently restricted to purified proteins. MAPD
complements existing approaches for the functional examination
of candidate binding sequences because this system permits
relative quantification and allows multiple endpoints (up to 100
DNA REs per experiment including internal reference controls).
In addition, the use of cell extracts in a rapid, low-cost 96-well
format enables complex experimental designs with large numbers
of samples and replication. An automated format is possible and
screening for inhibitors of binding or compounds that selectively
restore binding could be accomplished. A strength of the MAPD
approach over other binding methods is the inclusion of an
internal reference positive control (for example, p21, a strong
binding RE) and a negative control (WRNC, a nonbinding
sequence) within the multiplexed assay which provide for quality
control and normalization across experiments.
MAPD is a general methodology as demonstrated by detection
of not only p53 binding, but also the nuclear hormone receptor
ERa binding its RE (Figure S5). MAPD could be adapted to detect
the impact of multiple proteins in a transcription complex or to
evaluate multiple binding sites within native or artificially
Figure 6. Functional interrogation of bona fide p53 REs. A multiplex oligonucleotide panel of previously validated p53 REs [23] was assembled
(each oligonucleotide type on a unique microsphere bead) and tested for p53 binding. A) RE panel was treated with nuclear extracts from DOXO-
treated lymphoblastoid cells or SaOS-2 cells (p53-null) that were transiently transfected with plasmid pC53-SN3 (coding for human wt p53 cDNA
under control of the CMV promoter; see Materials and Methods). Equivalent quantities of p53 were used in each assay (as measured by Western
(shown in insert panel 6B) and ELISA). Following normalization to p21LWT value (p21=1), patterns of binding are similar for DOXO activated p53 and
ectopically expressed wt p53 (see also Figure S7A). The insert in Figure 6A displays the correlation between binding and luciferase expression for
several elements. Figure S7 displays the relationship between DOXO activated p53 binding and p53 ChIP. The panel included ConA and WRNC as
positive and negative controls, respectively. B) RE panel of beads was treated with nuclear extracts from either SaOS-2 cells (p53-null) that have been
transiently transfected with empty plasmid (p53 null, not shown), plasmid expressing p53 wt (p53 wt), plasmids expressing p53 mutant S121F or
R175H. Equivalent quantities of p53 were used in each assay (as measured by Western (shown in insert panel 6B); no binding was observed for p532/
2 SaOS-2 cells. Symbol (#) indicates RE retained binding in the S121F mutant. Bar values are mean6SEM (n=3). Note both the numerical difference
and the breaks in the scale of horizontal axes.
doi:10.1371/journal.pgen.1000462.g006
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functional evolution of p53 response elements across mammalian
species [43,49], co-evolution of the p53 protein, as well as rules for
p53 transactivation [50]. Because of MAPD’s sensitivity and
dynamic range, the impact of SNPs or mutations on binding can
be assessed providing a valuable tool in genomics research. We
found that subtle changes in binding sequence can have effects
that are not captured with existing computational models. Using
nuclear extracts from human cells expressing p53 mutants, R175H
and S121F, we observe a loss of binding and a change of binding
specificity, respectively, consistent with their effect on gene
expression. The correlation between binding in this nuclear
extract-based in vitro system and transactivation in mammalian
cells suggests the important role that sequence-specific p53
interactions play in transcriptional activation. MAPD will facilitate
studies of how variation in target binding sites affects binding and
fine-tuning the regulation of transcriptional networks as well as the
impact of polymorphic variation on master regulatory networks.
Materials and Methods
Cell Culture and Treatments
Human lymphoblastoid cells were grown in RPMI 1640 media
supplemented with 15% heat-inactivated fetal bovine serum
(Invitrogen Corp., Carlsbad, CA) and incubated at 5% CO2 at
37uC with 1% penicillin-streptomycin antibiotics (Invitrogen). The
cell lines GM12824 and GM12825 used for exposure were
purchased from Coriell Cell Repositories (Camden, NJ). Cells
were grown to ,8.5610
5 cells/mL before being exposed to
0.6 mg/mL (1 mM) doxorubicin (Sigma, St. Louis, MO) for
18 hours at 37uC. Human osteosarcoma cell lines SaOS-2 (HTB-
85, ATCC, Manassas, VA) and U2OS (HTB-96, ATCC) were
grown in McCoy’s A5 medium supplemented with 10% FBS and
100 mg/ml of penicillin and streptomycin. Cells were incubated at
37uC with 5% CO2.
Transient Transfection
For transient transfections, 1610
6 SaOS2 cells were seeded in a
100 mm plate. After 24 hours cells were transfected with 2 mgo f
purified endotoxin-free p53 expression vectors in the presence of
non-liposomal transfection reagent, FuGENE 6 (Roche Diagnos-
tics, Indianapolis, IN) according to manufacturer’s protocol.
U2OS cells were transfected with 2 mg pSG5-ERa expression
vector, provided by Dr. Gilbert Schonfelder, 24 hours prior to
preparation of extracts. Plasmids pC53-SN3[51] coding for
human p53 cDNA under the control of CMV promoter and
pCMV-Neo-Bam were provided by Dr. Bert Vogelstein. p53
mutants were made by site-directed mutagenesis according to the
manufacturer’s protocol (QuickChange Site-Directed Mutagenesis
kit, Stratagene, La Jolla, CA). p53 constructs were confirmed by
sequencing.
Nuclear Protein Extraction and Quantification
The presence of p53 in extracts was assessed by western blot
and TransAM p53 Transcription Factor assay (Active Motif).
Nuclear protein was extracted from non-treated and doxorubicin-
treated cells according to manufacturer’s protocol (Active Motif,
Carlsbad, CA) for ,8.8610
6 cells with the following modification.
Cells were transferred to 15 mL centrifuge tubes, spun at 4uC
(2006g, 5 min) and washed in 16 PBS/phosphatase. Protein
concentration was measured in triplicate using the BCA Protein
Assay kit (Pierce Biochemical, Rockford, IL), followed by a
fluorescence plate read using a HTS 7000 Bio Assay Reader
(Perkin Elmer, Waltham, MA).
Western Blot Analysis
Equal amounts of whole cell or nuclear extracts were separated
on NuPAGE BisTris gels and transferred to polyvinylidene
difluoride membranes (Invitrogen). The blots were probed with
primary antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) for p53 (PAb1801 and DO-1) and actin (C-11). For ERa
detection we used rabbit polyclonal anti-ERa (H-184, Santa
Cruz). Bands were detected using horseradish peroxide-conjugated
secondary antibodies (Santa Cruz) and the ECL Western Blotting
System (Amersham Biosciences, Piscataway, NJ).
General Oligonucleotide Design
The double-stranded DNA fragments incorporated a forward
oligonucleotide with a 24-nt ‘‘tag’’ at the 59 end linked to a 50-nt
fragment containing a sequence of interest. The forward
oligonucleotide was hybridized to a unique 24-nt ‘‘anti-tag’’
present on each FlexMAP bead type (Luminex, Austin, TX). The
50-nt modular fragment typically contained a 20-nt RE in the
middle of a 30-nt common backbone sequence (sequences are
described in Supporting Information). For p53 REs with a 1-nt
spacer (MDM2RE2, IGFBP3 and BAXA), the backbone length
was decreased to 29-nt. For ERa REs (17-nt in length), the
backbone sequence was increased to 33-nt. Reverse oligonucleo-
tides complementary to the 50-nt modular fragment were
synthesized with a 59 biotin moiety. All oligonucleotides were
synthesized by Invitrogen and are listed in the Supporting tables.
Preparation of Oligonucleotide-Bead Targets
We used 15 mL each bead type (approximately 2,500 beads) per
reaction. Beads were vortexed for 30 seconds and added to
double-stranded DNA containing the corresponding tag sequence
in an annealing buffer containing 5 mM Tris (pH 7.5), 10 mM
NaCl, and 0.5 mM EDTA. The final primer concentration was
1.5 mM. Annealing was performed in a PCR cycler (95uC for
5 min, followed by an incremental 5uC decrease, holding for
1 minute at each temperature, until reaching 45uC). Beads were
then placed in a filter plate (MultiScreenHTS-BV filter plate,
Millipore Corp., Bedford, MA) and washed several times with
Wash Buffer 1 (Assay Buffer A, Cytokine Reagent Kit, Bio-Rad
Laboratories, Hercules, CA).
Microsphere Protein-DNA Binding
Washed beads with conjugated DNA were then resuspended in
the appropriate volume of protein binding buffer (0.05 M KCl,
0.1 mM EDTA, 5 mM DDT, 0.05% Triton X-100, 10 mM
MgCl2, 1.0 mg/mL BSA, 0.5 mM ATP and 25 mM HEPES,
pH 7.6) supplemented with 150 pmoles non-competing double-
stranded oligo, WRNC. The noncompeting oligo from the
TransAm p53 kit (Active Motif, Carlbad, CA) was also effective.
In a typical binding assay (detection of p53 and ERa), beads were
resuspended in 50 mL protein binding buffer and supplemented
with 1.75 mg nuclear extracts from either treated or non-treated
cells, followed by thorough mixing for 15 seconds. Beads were
incubated with nuclear extracts for 1 hour at room temperature in
the dark, transferred onto a filter plate, washed 3 times with 50 mL
Wash Buffer 2 and incubated for 30 min with primary antibody.
For p53 detection, we used mouse monoclonal anti-p53 primary
antibody (1:500 dilution, clone DO-7, BD Biosciences, San Jose,
CA). For ERa detection, we used rabbit polyclonal anti-ERa
(1:500 H-184, Santa Cruz). Beads were washed 3 times with 50 mL
Wash Buffer 2 (50 mM KCl, 0.1 mM EDTA, 5 mM DTT,
0.5 mg/mL BSA, 0.05% Triton X-100, 10 mM MgCl2 and
25 mM HEPES, pH 7.6). The beads were then incubated with
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phycoerythrin-conjugated goat anti-mouse (p53) or 1:75 dilution,
R-phycoerythrin-conjugated goat anti-rabbit (both purchased
from Invitrogen) for 30 min and washed 3 times with 50 mL
Wash Buffer 2. Dilutions were prepared using a buffer made up of
PBS (5 mM Phosphate, 1.35 mM KCl, 68 mM NaCl) supple-
mented with 0.5% Tween 20 and 1% BSA. For signal
normalization, DNA-conjugated beads were treated separately
with phycoerythrin-conjugated streptavidin, 16 streptavidin-PE
diluted in Wash Buffer 1 for 20 min in the absence of any nuclear
extracts, then washed 3 times with 50 mL Wash Buffer 2. For
signal detection, beads were then re-suspended in 150 mL Wash
Buffer 1 and subjected to flow analysis using a Bio-Plex 200 (Bio-
Rad Laboratories) by following the manufacturer’s recommenda-
tion for instrument settings and calibration. All binding reactions
were conducted in triplicate.
Measurement of p53 Binding to SNP Alleles
The effect of SNPs on p53 binding to putative REs was
examined using the microsphere assay for protein-DNA binding as
described above. Each bead type was conjugated to double-
stranded oligonucleotides that contained either the predicted
strong or weak allele in separate annealing reactions (i.e., ADARB1
Strong and ADARB1 Weak were conjugated to bead 12).
Multiplexed allele sets were tested in parallel binding reactions.
To assess p53 binding, beads were incubated with nuclear extracts
derived from human either human lymphoblastoid (Figure 5) or
U2OS cells (Figure S8) that were treated with doxorubicin or
untreated (not shown). Negative and positive control oligonucle-
otide-bead targets were examined in each parallel reaction, and
untreated nuclear extracts were used as an additional negative
control.
Bead-Specific Corrections
Oligonucleotide density on beads varies among bead
types[14,52]. Therefore, bead-specific contribution to overall
signal must be taken into account. To account for bead-specific
effects, we used a 59 biotin moiety on the reverse oligonucleotide
bound to a phycoerythrin-conjugated streptavidin to measure the
maximal signal from each bead type used. For each bead type, the
protein-binding signal was normalized by the bead-specific signal,
independent of nuclear extracts and reported as relative binding.
In addition, FlexMap bead tag/anti-tag oligonucleotide sequences
should be evaluated for their similarity to target sequences and
binding to protein of interest.
Bioinformatics
We implemented a position weight matrix (PWM) for
quantitatively estimating DNA-protein binding and for predicting
novel REs [40]. In a standard PWM model, entries are the
probability of observing nucleotides at each position for the set of
sequences examined. The p53 RE PWM was computed from 59
published p53 REs (118 halfsites) (Table S2) [43]. The PWM score
for a p53 RE was calculated by scoring each half-site
independently, then summing the two. The ERa PWM was based
on 28 published ERa REs (Table S1). The binding PWM and
sequence logo was calculated by modifying the approach of
Veprintsev and Fersht [30]. Briefly, a binding difference matrix
was generated by subtracting the binding value for each of 60
ConA variants from the ConA binding value. Equations 2, A.1,
A.2 from the Appendix in Veprintsev and Fersht [30] were used to
generate a binding-based information content (IC) position weight
matrix. This IC PWM was used to create the sequence logo shown
in Figure 4B using the enoLOGOS software (http://biodev.hgen.
pitt.edu/cgi-bin/enologos/enologos.cgi), and was used to calculate
the predicted binding scores for the RE sequences plotted in
Figures 4D. These REs plotted in Figure 4D are the same as those
in Figure 6 and the sequences are listed in Table S1.
Supporting Information
Figure S1 Microsphere assay procedure. A) Double stranded
oligonucleotides containing sequences of interest are hybridized to
FlexMap beads and multiplex groups of beads are prepared. B)
Beads are incubated with nuclear extracts containing transcription
factor. C) Primary and secondary antibodies are added. D) Beads
are sorted and fluorescence signal is quantified for each bead type.
A critical technical feature of the assay is the use of FlexMAP
oligonucleotide-coated microspheres which allow for the attach-
ment of desired sequences to the bead. However, because the
density of oligonucleotide tags present on the surface of the beads
varies between bead types and bead batches, a bead type-specific
signal correction must be made in each experiment [14,52]. Each
double-stranded oligonucleotide tested had a biotin incorporated
at the free 59end (not shown in all drawings) and following the
hybridization, was conjugated with streptavidin-phycoerythrin and
read on the Bioplex 200 instrument. These biotin-streptavidin-
phycoerythrin values provide a readout for how many double-
stranded target oligonucleotides are present on the surface of each
bead type, and were used to normalize bead signals in each
experiment.
Found at: doi:10.1371/journal.pgen.1000462.s001 (0.07 MB PDF)
Figure S2 Tests of system components. A multiplex set of six
oligonucleotide-conjugated beads, each carrying a p53 binding site
(ConA, ConC, p21, PUMA, GADD45) and a negative control
(WRNC), was incubated under various conditions as shown and
analyzed for p53 binding as described in Supplemental Materials
and Methods. Lanes 1–5,7 and 8 show background and non-
specific interaction. A modest signal is detected following
incubation for 60 minutes with nuclear extracts from untreated
lymphoblastoid cells in the presence of primary and secondary
antibodies (lane 6). This signal was slightly enhanced in the
presence of free noncompeting oligo (lane 10) and attenuated in
the presence of a competing oligo (lane 11). A strong signal was
detected (lane 9) following incubation for 60 minutes with nuclear
extracts from lymphoblastoid cells treated with Doxo (30 mg/ml
for 18 hrs). In addition the signal was strongly enhanced in the
presence of free NC oligo (lane 12) for all p53 REs present in the
6-plex. The increased signal in the presences of noncompeting
oligonucleotide is likely due to blocking of nonspecific DNA-
binding proteins in the extract thereby enhancing specific p53
binding to target oligonucleotides. The signal was greatly
attenuated in the presence of 150 pmol competing oligonucleotide
(lane 13). The minimal signal for lane 13 indicates there is little if
any nonspecific binding of p53 to beads or antitag sequences, even
in the absence of noncompeting oligonucleotides. Note the two
scales of vertical axis. Values shown are mean for each bead
type+/2SD (n=3).
Found at: doi:10.1371/journal.pgen.1000462.s002 (0.77 MB PDF)
Figure S3 p53 binding in the presence of non-competing and
competing oligonucleotides. Specificity was ascertained by varying
amounts of competing oligonucleotide which was observed to
reduce specific binding in a concentration-dependent manner.
Similarly, the use of a noncompeting (or nonspecific) oligonucle-
otide, which blocks binding of nonspecific DNA binding proteins
to the target sequences, enhances the sensitivity as well as detection
limit and dynamic range of the assay. A multiplex set of 6
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(ConA, ConC, P21, PUMA, GADD45) and a negative control
(WRNC), were incubated with nuclear extracts (NT: non-treated;
Doxo: Doxorubicin-treated) for 60 minutes in the presence of
variable amounts of either non-competing (NC) or competing
(Comp) oligonucleotides and analyzed for p53 binding (see
Materials and Methods for sequence of oligonucleotides used).
A) The oligonucleotide set was incubated with decreasing amounts
of non-competing oligonucleotide (shown in pmoles per reaction)
and 1.75 micrograms of nuclear extracts from Doxo-treated cells.
B) Treatment with decreasing amounts of a competing oligonu-
cleotide and 1.75 micrograms of nuclear extract from Doxo-
treated cells. NC oligonucleotides were not added in this
experiment. Under these conditions ,1 pmole of competing
oligonucleotide is needed to eliminate p53 binding. The relative
binding intensity (value shown on vertical axes) was obtained for
each oligonucleotide as discussed in Materials and Methods. Note
breaks in the scale of vertical axes. Values shown are means for
each bead type6SD (n=3).
Found at: doi:10.1371/journal.pgen.1000462.s003 (0.06 MB PDF)
Figure S4 Concentration versus binding isotherm for nuclear
extracts containing activated p53. A multiplex set of 6 oligonu-
cleotide-conjugated beads, five carrying p53 REs (ConA, ConC,
P21, PUMA, GADD45) and one a negative control (WRNC), was
incubated with variable amounts of DOXO treated nuclear
extracts in the presence of 150 pmoles of non-competing
oligonucleotides for 60 minutes and analyzed for p53 binding.
A) Normalized binding for each oligonucleotide is shown with
varying amounts of nuclear extracts from Doxo-treated cells. The
relative binding intensity (value shown on vertical axes) was
obtained for each oligonucleotide as discussed in Materials and
Methods. Values shown are means for each bead type6SD (n=3).
Nonlinear regression was used to determine BMax and Kd. A
concentration of nuclear extract that was saturating for the p21
RE (1.75 ug) was chosen for the assay. An additional parameter
investigated included the impact of bead quantity on relative
binding. Bead quantity was varied from 2500 to 40,000 beads
(representing up to 80 bead types), each bead represented at equal
concentration. These experiments were carried out under varying
protein concentrations. Using 1.75 ug protein in the hybridization,
no effect of bead number on binding was observed. At lower
protein concentrations (less than 1.2 ug protein) binding values
were reduced for higher bead quantities in a linear, bead-quantity
dependent manner. Thus protein and bead/probe number need
to be optimized for a given system.
Found at: doi:10.1371/journal.pgen.1000462.s004 (0.05 MB PDF)
Figure S5 Detection of the interaction between ERa and its
cognate REs. An oligonucleotide set representing 8 previously
validated ERa REs (see supplementary materials for complete
sequences) was assembled and tested for ERa binding. The panel
included ConA and WRNC (from the p53 RE set). A) The ERa
RE panel was treated with nuclear extracts from cells with no
estrogen receptor (Lymph NT, lymphoblasts; Lymph Doxo,
Doxorubicin treated; U2OS NT, untransfected U2OS cells) or
pSG5-ERa-transfected U2OS cells (U2OS+pSG5-ERa). ER a
interaction with ERE sequences was assessed by treating with anti-
ERa antibody. Bar values are means for each bead type+/2SD
(n=3). The relative binding intensity (value shown on vertical
axes) was obtained for each oligonucleotide as discussed in
Materials and Methods. Nuclear extracts from cells that do not
express ERa (lymphocytes, Dox-treated lymphocytes and U2OS
cells) produced very low signal. In contrast, ERa binding to bona
fide EREs was strongly detected following incubation with extracts
from an ERa over-expressing cell line (U2OS2pSG5-ERa). B)
Experimental binding vs calculated PWM for ERa. Comparison
of experimental ERa binding (relative binding, n=3) vs calculated
ERa binding values (PWM). EBAG9, EFP, and COX7RP probes
contain ERa binding sites closely matching the ERE consensus
and displayed the highest level of binding to ERa. TERT, pS2,
LTF and KRT19 contain one or two changes from consensus and
showed moderate ERa binding, while CTSD had the lowest
binding signal. Values shown are means for each bead type6SD
(n=3). Within this small set of EREs, the binding was highly
correlated (R
2=0.78, p,0.001) with their sequence match to
consensus (based on calculated PWM values). For instance,
EBAG9, EFP, and COX7RP contain ERa binding sites closely
matching the ERE consensus and displayed the highest level of
binding to ERa. TERT, pS2, LTF and KRT19 contain one or
two changes from consensus and showed moderate ERa binding,
while CTSD had the lowest binding signal. Unexpectedly, ERa
binding was observed for the p53 positive and negative control
sequences ConA and WRNC. Further evaluation using an ERE
PWM model revealed that these sequences contain ERE-like
motifs that score as high as CTSD target sequences. This assay
requires further optimization.
Found at: doi:10.1371/journal.pgen.1000462.s005 (0.05 MB PDF)
Figure S6 Multiplex capability of MAPD using extracts from
untreated and treated cells. A total of 60 oligonucleotides, each
bearing a single nucleotide variation of a perfect p53 consensus
binding site (ConA=GGGCATGTCCGGGCATGTCC) was
generated. ConA sequence is shown in large letters. The CATG
core of each half-site is shown in a right-facing bracket. Systematic
base substitutions at all positions within ConA are shown in small
letters. For instance, 1G.C is an RE with the sequence
CGGCATGTCCGGGCATGTCC. In addition, a positive con-
trol bead (ConA RE) and a negative control bead (WRNC: lacks a
p53 binding RE) were also generated. Each oligonucleotide
variant was coated onto a unique microsphere type. Equal
amounts of each microsphere type were mixed to generate a
multiplex of 62 types of microspheres. Up to 82 oligonucleotides
have been successfully multiplexed (not shown). Beads were
incubated with nuclear extracts from untreated cells (NT,
checkered bar) or nuclear extracts from doxo-activated cell (Doxo,
black bars). Data from Doxo treated cells in this figure are also
plotted in Figure 3b. The relative binding intensity (value shown
on upper horizontal axis) was obtained for each oligonucleotide
(white bar) as discussed in Materials and Methods. Bar values are
means for each bead type6SD (n=3).
Found at: doi:10.1371/journal.pgen.1000462.s006 (0.67 MB PDF)
Figure S7 Comparative binding. A) Normalized binding values
from Doxo-induced p53 binding for p53 REs shown in Figure 6
are plotted against binding values for Wt p53 expressed in SaOS-
2 cells (data from Figure 6A). Binding values between the two
extracts are highly correlated, linear regression line is plotted,
r
2=0.86. B) Normalized binding values (n=8) from Doxo-
induced p53 binding for p53 REs shown in Figure 4C are plotted
against available ChIP-PET-SAGE values from Wei et al [31]
downloaded from the UCSC browser. A correlation coefficient of
r
2=0.58 (p=0.01) was observed for the comparison of MAPD-
determined relative binding vs ChIP-PET-SAGE for 8 known
p53 REs despite using different cell lines, treatments, and
methods.
Found at: doi:10.1371/journal.pgen.1000462.s007 (0.04 MB PDF)
Figure S8 Evaluation of eight p53 RE SNPs using nuclear
extracts containing activated p53 from DOXO treated U2OS cells
(same procedure as Figure 5).
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Table S1 Oligonucleotide sequences.
Found at: doi:10.1371/journal.pgen.1000462.s009 (0.07 MB
DOC)
Table S2 p53 response elements used to build position weight
matrix.
Found at: doi:10.1371/journal.pgen.1000462.s010 (0.10 MB
DOC)
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